Our pipeline at a glance

Updated July 27, 2021. Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly.

Download MSD Pipeline PDF

Phase 2 12 Programs
  • Pulmonary arterial hypertension MK-5475
  • Nonalcoholic steatohepatitis (NASH) MK-3655
  • Chikungunya virus Vaccine V184
  • HIV 1 infection/islatravir MK-8507/MK-8591B
  • Schizophrenia MK-8189
  • Treatment resistant depression MK-1942
  • Pancreas LENVIMA® (MK-7902) 1, 2
  • Bladder cancer TUKYSA® (MK-7119) 1
  • Esophageal cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Gastric cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Head & neck squamous cell carcinoma ladiratuzumab vedotin (MK-6440) 1, 3
  • Melanoma ladiratuzumab vedotin (MK-6440) 1, 3
  • Non-small cell lung cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Prostate cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Small cell lung cancer ladiratuzumab vedotin (MK-6440) 1, 3
  • Advanced solid tumors TUKYSA® (MK-7119) 1
  • Biliary tract cancer TUKYSA® (MK-7119) 1
  • Advanced solid tumors LYNPARZA® (MK-7339) 1, 3
  • Cervical cancer TUKYSA® (MK-7119) 1
  • Colorectal cancer TUKYSA® (MK-7119) 1
  • Endometrial cancer TUKYSA® (MK-7119) 1
  • Gastric TUKYSA® (MK-7119) 1
  • Non-small cell lung cancer TUKYSA® (MK-7119) 1
  • Melanoma cancer V937
  • Breast cancer V937
  • Cutaneous squamous cell carcinoma V937
  • Head and neck squamous cell carcinoma V937
  • Advanced solid tumors ladiratuzumab vedotin (MK-6440)1,3
  • Renal cell carcinoma MK-4280A
  • Non-small cell lung cancer MK-2140
  • Breast cancer MK-2140
  • Hematological Malignancies MK-1026
  • Non-small cell lung cancer quavonlimab (MK-1308) 2
  • Glioblastoma LENVIMA® (MK-7902) 1, 2
  • Hematological malignancies MK-42802
  • Non-small cell lung cancer MK-42802
  • Non-small cell lung cancer MK-4830
  • Small cell lung cancer MK-4830
  • Non-small cell lung cancer MK-58902
  • VHL- aRCC MK-6482 3 (EU)
  • Overgrowth syndrome MK-7075
  • Melanoma MK-76842
  • Biliary tract LENVIMA® (MK-7902) 1, 2
  • Breast cancer ladiratuzumab vedotin (MK-6440)1,3
  • Advanced solid tumors quavonlimab+ pembrolizumab (MK-1308A)
  • Colorectal cancer quavonlimab+ pembrolizumab (MK-1308A)
  • Hepatocellular carcinoma quavonlimab+ pembrolizumab (MK-1308A)
  • Melanoma quavonlimab+ pembrolizumab (MK-1308A)
  • Advanced solid tumors KEYTRUDA® (MK-3475)
  • Solid tumors V937
  • Respiratory syncytial virus MK-1654
  • Pneumococcal
  • Cytomegalovirus vaccine V160
Phase 3 24 Programs
  • Anti-Viral SARS-CoV-2 infection molnupiravir MK-44821
  • HIV-1 infection islatravir (MK-8591)
  • HIV-1 infection MK-8591A (Doravirine/Islatravir)
  • Non-small cell lung cancer MK-7684A
  • Cancer RCC MK-6482
  • Renal cell carcinoma (RCC) MK-1308A
  • Small cell lung cancer LYNPARZA® (MK-7339) 2
  • Colorectal LYNPARZA® (MK-7339) 1, 2
  • Non-small cell lung cancer LYNPARZA® (MK-7339) 1, 2
  • Head & neck squamous cell carcinoma LENVIMA® (MK-7902) 1, 2
  • Non-small cell lung cancer LENVIMA® (MK-7902) 1, 2
  • Melanoma cancer LENVIMA® (MK-7902) 1, 2
  • Gastric LENVIMA® (MK-7902) 1, 2
  • Colorectal LENVIMA® (MK-7902) 1, 2
  • Small cell lung cancer KEYTRUDA® (MK-3475)
  • Prostate cancer KEYTRUDA® (MK-3475)
  • Ovarian cancer KEYTRUDA® (MK-3475)
  • Mesothelioma cancer KEYTRUDA® (MK-3475)
  • Biliary tract cancer KEYTRUDA® (MK-3475)
  • Liver cancer KEYTRUDA® (MK-3475) (EU)
  • Gastric cancer KEYTRUDA® (MK-3475) (EU)
  • Cutaneous squamous cell carcinoma KEYTRUDA®
    (MK-3475) (EU)
  • Cervical cancer KEYTRUDA® (MK-3475) (EU)
  • Breast cancer TUKYSA® (MK-7119) 1
Under review 3 Programs
  • VHL- aRCC belzutifan (MK-6482) (US)
  • Cough gefapixant (MK-7264) (US, JPN)
  • Pneumoconjugate vaccine V114 (US, EU)

Therapeutic Key Areas

  • 1 - Being developed in collaboration.
  • 2 - Being developed in combination with KEYTRUDA.
  • 3 - Being developed as a monotherapy and in combination with KEYTRUDA.
  • 4 - Pipeline chart partially updated September 17, 2021 to reflect termination of LEAP-011 trial of KEYTRUDA in combination with Lenvima in platinum-ineligible first-line bladder cancer patients.

What do the phases of clinical trials mean?

Phase 1

Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always.  The trial often takes place in a hospital. The goals are to determine:

  • If the medicine or vaccine is safe
  • If there are any side effects
  • How the medicine is broken down by and discharged from the body
  • How much medicine is needed and how often
  • For a vaccine, researchers see if it causes the desired response from the body’s immune system

Phase 1 trials an take from six months to one year to complete.


Phase 2

Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:

  • How well the medicine or vaccine works
  • If the medicine or vaccine is safe
  • If there are any side effects
  • How much of the medicine or vaccine is needed and how often

Phase 2 trials can take from six months to one year or more to complete.


Phase 3

Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:

  • Confirm that the medication or vaccine is effective
  • Identify and monitor side effects
  • Compare the medicine or vaccine to commonly used treatments
Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.

Under review

The application has been submitted to the regulatory authorities for review.


No Duty to Update

The information contained in this chart was current as of July 27, 2021. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after July 27, 2021.

The chart reflects the company research pipeline as of July 27, 2021.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.